| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 181,70 | 182,40 | 18.11. | |
| 182,45 | 183,75 | 18.11. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Onto Innovation (ONTO) Caught Up in AI Physical Infrastructure Sell-Off | 2 | Insider Monkey | ||
| Mo | Onto Innovation authorizes $400 million buyback program | 1 | Investing.com | ||
| Mo | Onto Innovation launches $400M share repurchase program | 1 | Seeking Alpha | ||
| Mo | Can Onto Innovation Sustain Its Growth Momentum in 2027? | 2 | Zacks | ||
| 11.11. | Onto Innovation Inc.: Onto Innovation to Participate in Upcoming Investor Events | 861 | Business Wire | Onto Innovation Inc. (NYSE: ONTO) ("Onto Innovation," "Onto," or the "Company") today announced that its senior management team will participate in the following upcoming investor events:
RBC... ► Artikel lesen | |
| 10.11. | Onto Innovation Analysts Lower Their Forecasts After Q3 Results | 3 | Benzinga.com | ||
| 10.11. | Stifel cuts Onto Innovation stock price target on valuation | 12 | Investing.com | ||
| 10.11. | Needham cuts Onto Innovation stock price target on valuation | 21 | Investing.com | ||
| ONTO INNOVATION Aktie jetzt für 0€ handeln | |||||
| 10.11. | Onto Innovation Inc. Bottom Line Rises In Q3 | 2 | RTTNews | ||
| 10.11. | Onto Innovation outlines $430M-$450M Q4 revenue outlook as backlog reaches more than $1.3B | 16 | Seeking Alpha | ||
| 09.11. | Onto Innovation Q3 2026 Earnings Call Transcript | 4 | Benzinga.com | ||
| 09.11. | ONTO INNOVATION INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 09.11. | ONTO INNOVATION INC. - 8-K, Current Report | - | SEC Filings | ||
| 09.11. | Cantor Fitzgerald reiterates Onto Innovation stock rating on growth outlook | 6 | Investing.com | ||
| 28.10. | Aletheia Capital initiates Nanometrics stock with buy on ALD growth | 2 | Investing.com | ||
| 28.10. | Onto Innovation's Q3 Revenue Outlook: Can Sales Hit $400M? | 4 | Zacks | ||
| 21.10. | Onto Innovation: Diese KI-Aktie ist ein Favorit für 2027 | 927 | sharedeals.de | Die Aktie von Onto Innovation ist im Zuge der jüngsten Gewinnmitnahmen bei Halbleiterwerten deutlich unter Druck geraten. Angesichts starker Geschäftszahlen und wachsender Nachfrage durch den KI-Boom... ► Artikel lesen | |
| 20.10. | Cantor Fitzgerald bekräftigt "Overweight"-Einstufung für Onto Innovation | 9 | Investing.com Deutsch | ||
| 20.10. | Cantor Fitzgerald reiterates Onto Innovation stock rating at Overweight | 3 | Investing.com | ||
| 14.10. | Will Onto Innovation's Cash Balance Fuel Its Next Growth Phase? | 3 | Zacks |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 14,500 | -3,97 % | EQS-News: Formycon AG: Formycon verdoppelt Neunmonatsumsatz und treibt Umsetzung der Wachstumsstrategie FYB4Growth konsequent voran | EQS-News: Formycon AG
/ Schlagwort(e): 9-Monatszahlen
Formycon verdoppelt Neunmonatsumsatz und treibt Umsetzung der Wachstumsstrategie FYB4Growth konsequent voran
12.11.2026... ► Artikel lesen | |
| SOLESENCE | 1,640 | 0,00 % | Solesence expects at least $65M in shipped and on-hand orders by year-end, while pointing to potential >20% EBITDA longer term | ||
| RIBER | 5,900 | 0,00 % | Riber Reports Improved Results For The First Half Of 2026 | RIBER REPORTS IMPROVED RESULTS FOR THE FIRST HALF OF 2026 Revenues of €12.7m (+19%) and gross margin of €5.1m (+31%), representing 39.8% of revenuesPositive net income of €0.2m, compared with -€0.8m... ► Artikel lesen | |
| KOPIN | 2,749 | +1,44 % | Stifel bekräftigt Kaufempfehlung für Kopin nach starkem Quartalsergebnis | ||
| GAUZY | 4,770 | -5,36 % | GAUZY LTD: Gauzy Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal | TEL AVIV, Israel, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Gauzy Ltd. (Nasdaq: GAUZ) ("Gauzy" or the "Company"), a global leader in vision and light control technologies, today announced receipt of a delisting... ► Artikel lesen | |
| OBDUCAT | 0,033 | +26,92 % | NGM MARKET NOTICE: #26-72 Decision by the Disciplinary Committee regarding Obducat AB (publ) | ||
| GOMSPACE | 1,225 | -1,13 % | GomSpace Group AB: GomSpace reports continued profitable growth in Q3 and narrows full year guidance | GomSpace reports continued profitable growth in Q3 and narrows full year guidance
GomSpace delivers revenue growth with a 14% EBITDA margin in Q3 and sets 2030 financial targets of SEK 1.6 billion... ► Artikel lesen | |
| DOTZ NANO | 0,005 | -16,67 % | XFRA 57N: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| NANOFORM FINLAND | 0,773 | -2,64 % | Nanoform Finland Oyj: Nanoform Q2 2026 - Positive feedback from scientific advice meeting in the UK, significantly improved cash flow and discussions with CDMOs on sterile GMP for our Biologics technology initiated | Nanoform Finland Plc | Company Release | August 20, 2026 at 08:10:00 EEST
Nanoenzalutamide project continues with the communicated multitrack strategy supported by all partners. After a positive scientific... ► Artikel lesen | |
| VEECO INSTRUMENTS | 34,060 | 0,00 % | Veeco Instruments Inc.: Veeco Announces Upcoming Investor Events | ||
| ACACIA RESEARCH | 3,620 | -1,09 % | ACACIA RESEARCH CORP - 10-K/A, Annual Report | ||
| NVE | 71,50 | 0,00 % | Dividendenbekanntmachungen (02.11.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABM INDUSTRIES INC US0009571003 0,29 USD EUR ACUITY INC US00508Y1029 0,2 USD EUR AMERISERV FINANCIAL INC US03074A1025 0,03... ► Artikel lesen | |
| ADVANCE ZINCTEK | 0,298 | -0,67 % | ADVANCE ZINCTEK LIMITED: Proposed Capital Reduction of 3 Cents | ||
| LAMPETIA | 0,105 | 0,00 % | EQS-Adhoc: Lampetia AG: Verkauf der Lampetia Investments Engineering Ltd geplant | EQS-Ad-hoc: Lampetia AG / Schlagwort(e): Mergers und Acquisitions / Verkauf von Unternehmensteilen
Lampetia AG: Verkauf der Lampetia Investments Engineering Ltd geplant
06.11.2026... ► Artikel lesen | |
| NANOVIRICIDES | 1,060 | +1,92 % | NanoViricides, Inc. Has Filed its Quarterly Report - Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Separate Phase II Clinical Trials - One to Treat Ebola Bundibugyo Virus Disease, and Another to Treat Mpox | SHELTON, CT / ACCESS Newswire / November 17, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending... ► Artikel lesen |